Physician profile
Robert L Taylor
NPI 1063464808
$1,182.99
in general payments reported to CMS, 2019-2025
28 companies · $60.06 in 2025
The $60.06 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $447 · 2020: $297 · 2021: $218 · 2022: $15.87 · 2023: $94.48 · 2024: $50.27 · 2025: $60.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $204.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $308.92 | 2019-2021 | |
| Novo Nordisk INC | $88.16 | 2019-2023 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.26 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $74.21 | 2020-2021 | |
| Amgen INC. | $66.96 | 2020-2021 | |
| Glaxosmithkline, LLC. | $48.19 | 2019-2023 | Arexvy |
| Kowa Pharmaceuticals America, INC. | $43.76 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $40.91 | 2020 | |
| Phathom Pharmaceuticals, INC. | $37.52 | 2025 | Voquezna |
| Neos Therapeutics, LP | $36.57 | 2019 | |
| Antares Pharma, INC. | $36.07 | 2019 | |
| Scilex Pharmaceuticals INC. | $27.60 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.49 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.37 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $26.86 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $26.83 | 2019-2023 | Emgality, Jardiance |
| Exact Sciences Corporation | $22.54 | 2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $17.00 | 2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $16.92 | 2024 | |
| Almatica Pharma LLC | $16.35 | 2024 | Loreev Xr |
| Csl Behring | $15.87 | 2022 | |
| Shire North American Group INC | $14.83 | 2019 | |
| Kadmon Pharmaceuticals LLC | $14.59 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $14.29 | 2021 | |
| Eisai INC. | $13.63 | 2020 | |
| Alfasigma USA, INC. | $13.04 | 2020 | |
| Amarin Pharma, INC. | $11.65 | 2021 | |
| Clarus Therapeutics INC. | $9.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.